Bafna Pharmaceuticals Ltd (BAFNAPH) Financials - Quarterly Results, Profit & Loss, Balance Sheet, Cash Flow Bafna Pharmaceuticals Ltd reported sales of ₹11.57 Cr, operating profit of ₹-0.38 Cr (OPM -3.28%) and net profit of ₹-0.59 Cr for the quarter ended Sep 2019. Figures in ₹ crore, consolidated where available.
BAFNAPH quarterly results (₹ Cr) Metric Jun 2018 Sep 2018 Jun 2019 Sep 2019 Sales 11.95 8.84 6.85 11.57 Expenses 13.77 8.66 9.71 11.95 Operating Profit -1.82 0.18 -2.86 -0.38 OPM -15.23% 2.04% -41.75% -3.28% Other Income 0.09 -0.03 0.3 0.59 Interest 0.83 0.62 0.13 0.04 Depreciation 1 0.75 1.02 0.72 Profit before tax -3.56 -1.22 -3.71 -0.55 Tax -1.12% 4.1% -42.59% 7.27% Net Profit -3.52 -1.28 -2.13 -0.59 EPS in Rs -1.49 -0.54 -0.9 -2.49
BAFNAPH profit & loss, annual (₹ Cr) Metric Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Sales 97 85 65 46 44 42 Expenses 114 85 71 81 57 41 Operating Profit -18 1 -6 -35 -13 1 OPM -18% 0.6% -9% -77% -30% 2.9% Other Income 43 2 1 31 1 -22 Interest 13 13 11 7 2 0 Depreciation 6 5 4 4 3 3 Profit before tax 6 -15 -20 -15 -17 -24 Tax -2% -1% -4% 15% 6% 0% Net Profit 6 -15 -19 -17 -18 -24 EPS in Rs 3.31 -7.52 -10.23 -7.08 -7.98 -104.54 Dividend Payout 0% 0% 0% 0% 0% 0%
BAFNAPH balance sheet (₹ Cr) Metric Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Equity Capital 19 19 24 24 2 Reserves 39 24 14 -5 49 Borrowings 80 82 47 46 3 Other Liabilities 54 53 54 54 17 Total Liabilities 193 178 138 119 71 Fixed Assets 53 49 45 37 35 CWIP 0 0 0 0 0 Investments 17 17 0 0 0 Other Assets 123 113 93 82 36 Total Assets 193 178 138 119 71
BAFNAPH cash flows (₹ Cr) Metric Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Cash from Operating Activity 1 -1 -7 -2 -34 Cash from Investing Activity 0 -5 38 15 33 Cash from Financing Activity -1 6 -31 -14 7 Net Cash Flow 0 0 0 0 6 Free Cash Flow -1 -1 40 3 -36 CFO/OP 175% 16% 20% 14% -2,812%
BAFNAPH ratios Metric Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Debtor Days 292 303 195 208 52 Inventory Days 90 118 102 122 208 Days Payable 208 168 273 519 229 Cash Conversion Cycle 174 253 24 -190 31 Working Capital Days 106 -39 -113 -210 90 ROCE -2% -7% -36% -22% -3%